Skip to main content
Premium Trial:

Request an Annual Quote

Francis Collins, Carlos Brody, James Collins, Michael Eisen, Jonathan Pritchard

Francis Collins, director of the National Human Genome Research Institute, said this week that he will step down from his post on Aug. 1 to focus on “writing projects and other professional opportunities.”
Collins has been director of NHGRI since April 1993 and led the Human Genome Project to its completion in 2003. He also guided a number of follow-up initiatives, such as the International HapMap Project, the Encyclopedia of DNA Elements, the Knockout Mouse Project, the Mammalian Gene Collection, the Cancer Genome Atlas, the Molecular Libraries Initiative, and the Human Microbiome Project. Collins also founded an intramural program in genomics within the National Institutes of Health in 1993.
Alan Guttmacher, deputy director of NHGRI, will be appointed acting director of the institute on Aug. 1. NIH said that it will soon begin a formal search process for a permanent NHGRI director.

The Howard Hughes Medical Institute has named fifty-six new biomedical scientists as HHMI investigators.
Among the new investigators are:  
Carlos Brody, associate professor of molecular biology at Princeton University; James Collins, professor of biomedical engineering at Boston University; Michael Eisen, associate professor of molecular and cell biology at the University of California, Berkeley; and Jonathan Pritchard, professor of human genetics at the University of Chicago.
Brody’s work has focused on computer models of neurons in the prefrontal cortex and the decision-making process in that brain region. He created a computer model using data from monkey studies in which the animals were trained to make decisions and select choices among options to simulate how a neuronal process flips from storing information in short-term memory weighing the options at hand to enabling a decision.
Collins’ lab has several focus areas. He is working on a combination of computational and experimental methods to reverse engineer gene regulatory networks in microbes and higher organisms. In the field of synthetic biology, he and his lab construct synthetic gene networks for several biotechnology applications.
Eisen’s lab includes geneticists, biochemists, and computer scientists who study fruit flies and other organisms such as fungi to learn how the genome specifies animal form as well as their shape. They look at the evolution of gene expression, its regulation, and its variation. Eisen also spearheaded the effort to sequence twelve Drosophila species and co-founded the Public Library of Science, which publishes peer-reviewed open access journals.
Pritchard studies various aspects of human genetic variation, applying mathematical and computational techniques. He uses computationally intensive approaches such as Markov chain Monte Carlo to examine large datasets to look at gene mapping of complex traits, the history of human populations, and the factors that contribute to genome variation and evolution.  

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.